NASDAQ:PRQR ProQR Therapeutics (PRQR) Stock Price, News & Analysis $1.66 +0.02 (+1.22%) (As of 10:39 AM ET) Add Compare Share Share Today's Range$1.63▼$1.6650-Day Range$1.64▼$2.0252-Week Range$1.11▼$3.29Volume6,204 shsAverage Volume209,991 shsMarket Capitalization$135.06 millionP/E RatioN/ADividend YieldN/APrice Target$3.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ProQR Therapeutics alerts: Email Address ProQR Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside105.8% Upside$3.38 Price TargetShort InterestHealthy0.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.88Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.37) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.27 out of 5 starsMedical Sector529th out of 896 stocksPharmaceutical Preparations Industry244th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingProQR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageProQR Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about ProQR Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.37% of the float of ProQR Therapeutics has been sold short.Short Interest Ratio / Days to CoverProQR Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProQR Therapeutics has recently decreased by 18.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldProQR Therapeutics does not currently pay a dividend.Dividend GrowthProQR Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRQR. Previous Next 3.3 News and Social Media Coverage News SentimentProQR Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ProQR Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows2 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of ProQR Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.65% of the stock of ProQR Therapeutics is held by institutions.Read more about ProQR Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.37) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProQR Therapeutics is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProQR Therapeutics is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProQR Therapeutics has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ProQR Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Digital Mavericks Media1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.Click here to check it out. About ProQR Therapeutics Stock (NASDAQ:PRQR)ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Read More PRQR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRQR Stock News HeadlinesJune 30, 2024 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Upgraded to Hold by StockNews.comMay 13, 2024 | finance.yahoo.comShareholders in ProQR Therapeutics (NASDAQ:PRQR) are in the red if they invested five years agoJuly 5, 2024 | Chaikin Analytics (Ad)50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the start of the year.May 10, 2024 | markets.businessinsider.comProQR’s Axiomer Platform Technology Shows Promise: Analyst Maintains Buy Rating on Robust Editing Efficacy and Clinical Development PotentialMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Promising RNA Editing Technology and Solid Financial FootingMay 9, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Announces First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | globenewswire.comProQR Announces First Quarter 2024 Operating and Financial ResultsMay 8, 2024 | markets.businessinsider.comBuy Recommendation on ProQR’s Innovative RNA Editing Platform and Promising Clinical ProspectsJuly 5, 2024 | Chaikin Analytics (Ad)50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the start of the year.May 8, 2024 | stockhouse.comProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer(TM) RNA Editing Program Targeting NTCP for Cholestatic DiseasesMay 8, 2024 | finance.yahoo.comProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic DiseasesApril 24, 2024 | stockhouse.comProQR Highlights Upcoming Presentations on Axiomer(TM) RNA Editing at ASGCT 27th Annual MeetingApril 23, 2024 | globenewswire.comProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024April 22, 2024 | finance.yahoo.comProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingApril 22, 2024 | globenewswire.comProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingApril 21, 2024 | uk.investing.comProQR retains key patent for RNA editing technologyApril 20, 2024 | stockhouse.comProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP PortfolioApril 19, 2024 | globenewswire.comProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP PortfolioApril 8, 2024 | finance.yahoo.comProQR Therapeutics N.V. (PRQR)March 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic DisordersMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing PlatformMarch 14, 2024 | finance.yahoo.comProQR Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 13, 2024 | globenewswire.comProQR Announces Year End 2023 Operating and Financial ResultsFebruary 18, 2024 | finance.yahoo.comPRQR Mar 2024 2.500 callFebruary 16, 2024 | wsj.comProQR Therapeutics N.V.February 15, 2024 | finance.yahoo.comProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA EditingJanuary 30, 2024 | stocknews.com4 Biotech Stocks With Massive Buy PotentialSee More Headlines Receive PRQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/05/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRQR CUSIPN/A CIK1612940 Webwww.proqr.com Phone(188) 166-7000FaxN/AEmployees156Year FoundedN/APrice Target and Rating Average Stock Price Target$3.38 High Stock Price Target$5.00 Low Stock Price Target$2.00 Potential Upside/Downside+105.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,430,000.00 Net Margins-260.75% Pretax Margin-258.78% Return on Equity-61.58% Return on Assets-19.43% Debt Debt-to-Equity RatioN/A Current Ratio3.11 Quick Ratio3.11 Sales & Book Value Annual Sales$7.05 million Price / Sales18.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book2.98Miscellaneous Outstanding Shares81,360,000Free Float74,521,000Market Cap$133.43 million OptionableOptionable Beta0.42 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Domenico Valerio Ph.D. (Age 68)Founder & Independent Chairman of Supervisory Board Comp: $80.46kMr. Daniel Anton de Boer (Age 41)Founder, CEO & Member of Management Board Comp: $1.3MMr. Rene K. Beukema (Age 60)Chief Corporate Development Officer, General Counsel & Member of Management Board Comp: $994.88kDr. Gerard Platenburg (Age 60)Co-Founder & Chief Scientific Officer Comp: $23.92kMr. Jurriaan Dekkers (Age 48)Chief Financial Officer Ms. Sheila Sponselee (Age 40)Chief People & Operations Officer Ms. Sarah Cue KielyVice President of Investor Relations & Corporate CommunicationsMs. Sandra van der KolkJunior Financial ControllerMore ExecutivesKey CompetitorsSIGA TechnologiesNASDAQ:SIGAApplied TherapeuticsNASDAQ:APLTY-mAbs TherapeuticsNASDAQ:YMABHeron TherapeuticsNASDAQ:HRTXPepGenNASDAQ:PEPGView All CompetitorsInstitutional OwnershipVirtu Financial LLCSold 8,961 shares on 5/20/2024Ownership: 0.032%Ikarian Capital LLCBought 10,958 shares on 5/17/2024Ownership: 0.594%M28 Capital Management LPSold 891,102 shares on 5/15/2024Ownership: 1.253%EP Wealth Advisors LLCBought 11,500 shares on 5/14/2024Ownership: 0.014%Acadian Asset Management LLCBought 24,763 shares on 5/10/2024Ownership: 0.030%View All Institutional Transactions PRQR Stock Analysis - Frequently Asked Questions Should I buy or sell ProQR Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRQR shares. View PRQR analyst ratings or view top-rated stocks. What is ProQR Therapeutics' stock price target for 2024? 4 brokerages have issued 12-month price targets for ProQR Therapeutics' stock. Their PRQR share price targets range from $2.00 to $5.00. On average, they predict the company's stock price to reach $3.38 in the next twelve months. This suggests a possible upside of 105.8% from the stock's current price. View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts. How have PRQR shares performed in 2024? ProQR Therapeutics' stock was trading at $1.98 at the beginning of 2024. Since then, PRQR stock has decreased by 17.2% and is now trading at $1.64. View the best growth stocks for 2024 here. Are investors shorting ProQR Therapeutics? ProQR Therapeutics saw a decline in short interest in June. As of June 15th, there was short interest totaling 196,600 shares, a decline of 18.5% from the May 31st total of 241,200 shares. Based on an average trading volume of 124,600 shares, the short-interest ratio is currently 1.6 days. Approximately 0.4% of the shares of the company are sold short. View ProQR Therapeutics' Short Interest. When is ProQR Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our PRQR earnings forecast. How were ProQR Therapeutics' earnings last quarter? ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.02. The biopharmaceutical company had revenue of $4.83 million for the quarter, compared to the consensus estimate of $3.31 million. ProQR Therapeutics had a negative net margin of 260.75% and a negative trailing twelve-month return on equity of 61.58%. What ETF holds ProQR Therapeutics' stock? Morningstar US Small Growth holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio. What other stocks do shareholders of ProQR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX). How do I buy shares of ProQR Therapeutics? Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRQR) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.